Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Veracyte Inc Logo

ARKW Holdings of Veracyte (VCYT) - Updated Daily

BioinformaticsGenomics
Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
November 21, 2022
SELL32.892k0.0761%ARKW
November 18, 2022
SELL481.0000.0012%ARKW
November 17, 2022
SELL15.992k0.0368%ARKW
November 15, 2022
SELL20.082k0.0512%ARKW
January 7, 2022
BUY14.800k0.0148%ARKW

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKWARKG$27.89
⚖️Weighting🧢Market Cap
1.58%$2.00b
🏋🏿‍♂️Weight Rank In ARKW🧮Price to Sales
207.06
🏋️‍♀️Weight Rank Across All Funds🌏Country
21🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$14.851.1%
Description
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Website
www.veracyte.com